March 23, 2018 / 10:04 AM / a month ago

BRIEF-Anticancer Agent Lenvima Approved For Additional Indication Of Unresectable Hepatocellular Carcinoma In Japan

March 23 (Reuters) - Merck & Co Inc:

* ANTICANCER AGENT LENVIMA® (LENVATINIB MESYLATE) APPROVED FOR ADDITIONAL INDICATION OF UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC) IN JAPAN, FIRST APPROVAL WORLDWIDE FOR LENVIMA FOR HCC

* MERCK & CO INC - ‍HAVING RECEIVED APPROVAL OF INDICATION, EISAI WILL RECEIVE A DEVELOPMENT MILESTONE PAYMENT FROM MERCK​

* MERCK & CO - NO CHANGES TO EISAI’S FINANCIAL RESULTS FORECASTS FOR FISCAL YEAR ENDING MARCH 31, 2018 BASED ON RECEIPT OF MILESTONE PAYMENT FROM MERCK​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below